On Wednesday, Shares of U.S. Bancorp (NYSE:USB), lost -1.34% to $44.09.
U.S. Bancorp (USB) declared that Richard Davis, chairman, president and CEO, will take part in a discussion regarding the Company at Bernstein’s 31st Annual Planned Decisions Conference. The session starts at 8:00 a.m. EDT on Thursday, May 28, 2015, in New York City and will comprise information about U.S. Bancorp’s financial performance and corporate strategies.
U.S. Bancorp, a financial services holding company, provides a range of financial services in the United States. It offers depository services, which comprise checking accounts, savings accounts, and time certificate contracts; and lending services, such as traditional credit products, in addition to credit card services, leasing, financing and import/export trade, asset-backed lending, agricultural finance, and other products.
Shares of ENSCO PLC (NYSE:ESV), declined -0.65% to $24.50, during its last trading session.
Ensco plc (ESV) declared that its Board of Directors has declared a regular quarterly cash dividend of US$0.15 per Class A ordinary share payable on 19 June 2015. The ex-dividend date for this payment is predictable to be 4 June 2015, with a record date of 8 June 2015.
Ensco declared at its annual general meeting of shareholders on 18 May 2015 that the vast majority of shares cast were voted “For” all proposals in its 1 April 2015 proxy statement.
Ensco plc provides offshore contract drilling services to the oil and gas industry worldwide. The company operates through three segments: Floaters, Jackups, and Other.
At the end of Wednesday’s trade, Shares of Baxter International Inc. (NYSE:BAX), lost -0.77% to $67.95.
Baxter International Inc. (BAX) declared that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental drug application to establish its Sabinanigo, Spain, facility as an approved manufacturing site for 0.9% Sodium Chloride Injection, USP, for the U.S. market.
The approval comprises product presentations in 250 ml, 500 ml and 1000 ml, which Baxter has been distributing in the U.S. to alleviate a drug shortage with the knowledge of the FDA. All three of these product presentations of 0.9% Sodium Chloride Injection, USP, more commonly known as saline, have been listed in drug shortage databases maintained by FDA and the American Society of Health-System Pharmacists over the past two years.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products.
Finally, Bank of New York Mellon Corp (NYSE:BK), ended its last trade with 0.18% gain, and closed at $43.62.
The median return of the BNY Mellon U.S. Master Trust Universe, a fund-level tracking service, was 2.4% for the first quarter of 2015, marking the second straight quarter of positive performance. Non-U.S. equities (+4.1%) and real estate (+3.2%) contributed most to the positive Q1 results. The Master Trust Universe posted a one-year return of 7.2%, underperforming its five-year average of 9.4%.
With a market value of more than $2.5 trillion and an average plan size of $4.2 billion, the BNY Mellon U.S. Master Trust Universe is a fund-level tracking service that can be used to make peer comparisons of both performance and asset allocation results. The Universe comprises of 588 corporate, foundation, endowment, public, Taft-Hartley, and health care plans.
The Bank of New York Mellon Corporation, an investment company, provides financial products and services to institutions, corporations, and high net worth individuals in the United States and internationally. It operates through two segments, Investment Administration and Investment Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
